I confess: I'd always hated IBM Corp. (NYSE: IBM); never could stand Big Blue. The company was always too unfocused for my taste.
Its boardroom underwhelmed, too, allowing Microsoft Corp. (Nasdaq: MSFT) and Amazon.com Inc. (Nasdaq: AMZN) to outmaneuver and shut it out of the outrageously lucrative cloud.
IBM's hardware is low margin, and its software doesn't do much better.
That's why I've never suggested owning IBM. It was a non-starter. A losing bet.
Until now...
What I saw at a conference near my Bay Area home has me convinced that IBM has transformed from a "dog" into a scorching, ground-floor opportunity.
I know how that sounds: How could a 107-year-old tech company with fading fortunes turn on a dime to become one of 2018's hottest buy recommendations?
Well, let me explain - and show you what it showed me...
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.
I've been hearing about bit coin from my son. I would like more info on it.
I lost money on IBM by your advice